Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
|Videos|May 17, 2021
You're Invited!
Author(s)John J. Miller, MD
John J. Miller, MD, formally invites you to the Annual Psychiatric Times® World CME Conference™.
Advertisement
John J. Miller, MD, invites you to join us for the hybrid model Annual Psychiatric Times® World CME Conference™ on September 30, 2021 through October 2, 2021. You can join via video call, or in San Diego, to earn CME credits.
Dr Miller is Medical Director, Brain Health, Exeter, NH; Editor in Chief, Psychiatric TimesTM; Staff Psychiatrist, Seacoast Mental Health Center, Exeter, NH; Consulting Psychiatrist, Exeter Hospital, Exeter, NH; Consulting Psychiatrist, Insight Meditation Society, Barre, MA.
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
Post Hoc SOLARIS Data Support Stabilization and Remission With Subcutaneous Olanzapine
3
Hippocampal Generative Processes During Sleep Support Rapid Learning of New Associations
4
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
5